

SULFA-B™

ORAL PASTE ANTIBIOTIC MUCOLYTIC FOR HORSES


ACTIVE CONSTITUENTS: 325mg/mL SULFADIAZINE, 65mg/mL TRIMETHOPRIM, 20mg/mL BROMHEXINE HYDROCHLORIDE



Peace of mind when you can't be there for every dose


For treatment of productive upper respiratory tract infections in horses where those infections are susceptible to Sulfadiazine potentiated with Trimethoprim and where the mucolytic effect of Bromhexine HCL is desired.

- Antibiotic and mucolytic action
- Reduced recovery time for acute respiratory infections
- Significant blood levels achieved within 30 minutes
- Ready to use pre-filled syringes



SULFA-B™ ORAL PASTE		BROMOTRIMIDINE PASTE
ACTIVE CONSTITUENTS	325mg/mL Sulfadiazine, 65mg/mL Trimethoprim, 20mg/mL Bromhexine HCl	450mg/g Sulfadiazine, 90mg/g Trimethoprim, 9mg/g Bromhexine HCl
SPECIES	Equine	Equine
ROUTE OF ADMINISTRATION	Oral	Oral
DOSE RATE	5mL/100kg twice a day, 12 hourly for 5 days	20mL/450kg twice daily

SULFA-B™ is a trademark of Abbey Laboratories Pty Ltd.



SULFA-B™

ORAL PASTE ANTIBIOTIC MUCOLYTIC FOR HORSES

ACTIVE CONSTITUENTS: 325mg/mL SULFADIAZINE, 65mg/mL TRIMETHOPRIM, 20mg/mL BROMHEXINE HYDROCHLORIDE

INDICATIONS

SULFA-B™ is indicated for the treatment of productive upper respiratory tract infections in horses where those infections are susceptible to Sulfadiazine potentiated with Trimethoprim and where the mucolytic effect of Bromhexine HCl is desired.

The Sulfonamide acts by blocking the biosynthesis of folic acid in the bacterial cell and the Trimethoprim interferes in the reduction process of folic acid in the bacterial cell to the biologically active form tetrahydrofolate. Bromhexine HCl aids in the removal of the thick, tenacious mucoid secretions in the airways by reducing viscosity of the acid mucopolysaccharide fibers from the mucous glands in nose, throat and lungs. This facilitates the availability of the antibacterial agents to the infected areas to reduce recovery time following acute respiratory infection. Pharmacokinetic studies carried out, show a rapid absorption of the active antibacterial agents with significant blood levels after 30 minutes and a peak level after 2-3 hours. The half-lives of Sulfadiazine and Trimethoprim are compatible, in the region of 8-10 hours and twice daily dosage at the recommended levels produces a steady state drug blood level after 5 sequential doses. Subsequent dosing to complete a typical 5 day course does not result in the accumulation of drug blood levels to any undesirable level.

DIRECTIONS FOR USE

Contraindications

SULFA-B™ is generally well tolerated with a low incidence of adverse reactions. Do not use in renal or hepatic dysfunction or with known previous hypersensitivity to Sulfonamides. Take care with gut superinfection which can lead to toxic megacolon. The animal should have access to food and cool, clean water. Discontinue treatment if there is marked inappetence or signs of abdominal discomfort. Long term therapy may require replenishing treatment with multi-vitamins, vitamin B12 and folic acid supplements.

DOSAGE AND ADMINISTRATION

Horses: 5mL/100kg twice a day 12 hourly for 5 days

To administer, remove cap from the syringe and direct the nozzle of the syringe into the side of the horse's mouth. Depress the plunger to dispense the desired dose towards the back of the tongue. Keep the mouth closed for a few seconds to make sure the dose is swallowed. Replace cap after use.

WITHHOLDING PERIODS

SULFA-B™ should not be administered later than 28 days before slaughter for human consumption.

The ingredients of SULFA-B™ are not performance enhancing but a treatment sheet and advice from veterinarian on the local competition rules would be required prior to competition.

DISPOSAL

Dispose of empty containers by wrapping with paper and putting in garbage.

STORAGE

Store below 25°C (air conditioning). Protect from light.

APVMA Approval No: 49953/1197

SULFA-B™ is a trademark of Abbey Laboratories Pty Ltd.